Vascular Cognitive ImpairmentNCT04999813
Study on Early Brain Injury Mechanism and Comprehensive Intervention of VCI
A study testing Comprehensive intensive intervention in people with Vascular Cognitive Impairment, run by Zhongnan Hospital at 1 site in China.
Trial summary
Alzheimer's disease (AD) and vascular dementia (VaD) are the most common forms of senile dementia. Although the animal research of dementia has made remarkable progress, clinical trials of drugs for AD pathology have failed in recent years. Read more about this study
- Who is it for?
- Ages 50 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Vascular Cognitive Impairment
- What is being tested?
- Comprehensive intensive intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 600 participants
- Where
- 1 siteChina
- Study dates
- 1 Jul 2020to Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- ①Healthy volunteers or VCIND patients(Diagnostic criteria comply with the "Guidelines for the Diagnosis and Treatment of Vascular Cognitive Impairment" formulated by the Dementia and Cognitive Impairment Group of the Neurology Branch of the Chinese Medical Association);
- ②Age between 50-70 years old;
- ③Able to accept and cooperate in completing various instrumental examinations and neuropsychological examinations Scale testing;
- ④Agree to sign an informed consent form.
Who cannot join
- ①Combined with other serious diseases, life expectancy is less than 3 years;
- ②Patients with vision and hearing impairment that significantly affect cognitive testing;
- ③Severe heart, brain, lung, kidney and other diseases;
- ④Have a history of psychoactive substance abuse;
- ⑤Have other serious physical diseases that affect cognitive testing, such as coma, epilepsy, hypothyroidism , Hypoxemia, etc.;
- ⑥have a history of mental illness;
- ⑦have MRI contraindications, unwilling to participate in research and unconditional follow-up.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Zhongnan Hospital
Wuhan, Hubei, 430071
Mengwei Hu, Master, +86-027-67811757
About this study
Official title: Study on Early Brain Injury Mechanism and Comprehensive Intervention of Vascular Cognitive Impairment
Alzheimer's disease (AD) and vascular dementia (VaD) are the most common forms of senile dementia. Although the animal research of dementia has made remarkable progress, clinical trials of drugs for AD pathology have failed in recent years. The study of dementia based on cell and animal model generally aims at a single mechanism and target, and its results are quite different from the real clinical environment. More and more studies suggest that investigators should shift the focus of research to the early stage of cognitive impairment before dementia. Prevention is more important than cure, and intervention against multi-factors and multi-targets has become an important consensus. A large number of studies have shown that the mechanism of vascular brain injury plays an important role in the pathogenesis of AD and VaD, and many vascular risk factors are interventionable to some extent. Therefore, based on the clinical cohort, in-depth study of vascular cognitive impairment (Vascular cognitive impairment, VCI) has important clinical significance for the effective prevention and treatment of AD and VaD.
The leading team of the project has focused on VCI research for a long time. After nearly 20 years of experimental research and preliminary clinical observation, it is proposed that chronic cerebral ischemia can not only be a clinical disease entity, but also an important pathological basis for the early onset of VCI. This view has recently been supported by a number of authoritative international research evidence. Big data's study of 1171 patients with AD reported by Nature Commun in 2016 shows that the early pathological changes of AD may not be a cascade of amyloid protein (Aβ), but a decrease in cerebral blood flow. Therefore, this project intends to establish an early clinical research cohort of VCI to focus on three key issues in VCI research and clinical practice: (1) the theory that cerebral hypoperfusion may be an important pathological basis for the occurrence and development of VCI needs direct evidence support from clinical studies, and its mechanism needs further elucidation. (2) Based on the fusion of multimodal MRI of VCI vascular brain injury pathology and PET imaging markers of Aβ molecular pathology, a multivariate VCI cognitive evaluation model is constructed, and its sensitivity and specificity may be better than the existing VCI diagnostic standards. (3) the protective effect of early comprehensive intervention of vascular risk factors on cognitive decline in VCI may be more effective than that of single risk factor.
Read more
The first part of this project is to establish a study cohort of non-demented vascular cognitive impairment(VCIND). Neurocognitive function assessment combined with multimodal MRI including ASL, DCE, DTI and BOLD techniques were used to observe the role of cerebral hypoperfusion in the early stage and progression of VCI. At the same time, the relationship between the changes of blood-brain barrier and neural network and cognitive decline was dynamically observed to verify and explore the effect and mechanism of cognitive impairment caused by cerebral hypoperfusion. The second part studies the pathology of vascular brain injury based on MRI and the molecular pathology of A β based on PET and the relationship between Aβ molecular pathology and cognitive impairment, including the main factors affecting cognitive function, and uses artificial intelligence (AI) algorithm to develop a multiple quantitative evaluation system of VCI cognitive function, which is mainly based on the fusion of MRI and PET image markers. In the third part, a multicenter randomized controlled clinical cohort study was conducted to observe the cognitive protective effect of comprehensive intensive intervention of vascular risk factors on early VCI, so as to provide direct clinical evidence and intervention model for the prevention and treatment of VCI. The topics of the above three aspects covered by this project are closely related, which is not only a key scientific problem, but also an important clinical problem to be solved in the diagnosis and treatment of VCI.
The study of this project is expected to further clarify the role and mechanism of cerebral hypoperfusion in VCI, provide a new theoretical basis for the prevention and treatment of dementia, and develop a quantitative evaluation system of VCI cognitive function mainly based on imaging technology and AI algorithm, so as to provide a more accurate and convenient diagnostic tool for early clinical identification and scientific research of VCI. Draw up the early comprehensive intervention paradigm of VCI based on vascular risk factors and popularize it in clinic, gradually form an expert consensus, enrich and update the guidelines for diagnosis and treatment of dementia, and effectively improve the level of prevention and treatment of dementia related to VCI.
Read the detailed description
The main research contents of this project focus on the above three key issues: to study the role and mechanism of cerebral hypoperfusion in the early pathogenesis of VCI; to establish a predictive model for early diagnosis of MRI vascular brain damage and PET-A β pathology; to explore the clinical effect of early comprehensive intensive intervention of VRF on the prevention and treatment of VCI.
- To explore the role and mechanism of cerebral hypoperfusion in the early brain damage of VCI.
- The relationship between vascular risk factor burden and VCI Vascular risk factor (VRF) is not only an important factor in the occurrence and development of VCI, but also the main intervention target. Elucidating the relationship between VRF and VCI can provide an important theoretical basis for its early prevention and treatment. Some clinical studies have shown that long-term VRF burden is closely related to the decrease of global cerebral blood flow in young and middle-aged people without stroke, suggesting that there is a close relationship between VRF, cerebral hypoperfusion and cognitive impairment, but it needs to be further clarified in clinical cohort studies. In this project, a clinical cohort of VCIND was established, including 500 middle-aged and elderly people with VRF burden, and their complete demographic information was collected. The overall VRF burden was assessed by the Framingham Stroke risk Assessment scale, and the subjects were divided into low risk group (10-year stroke risk < 10%), medium risk group (10-year stroke risk 10%) and high-risk group (10-year stroke risk > 20%) for follow-up. The changes of cognitive function in baseline and 3-year follow-up period were measured. The relationship between VRF burden and cognitive decline in VCI was analyzed by mixed effect model, and whether decreased cerebral perfusion mediated this correlation was analyzed by mediating effect model.
- The role of cerebral hypoperfusion in the early brain damage of VCI. Many experimental studies have shown that chronic cerebral hypoperfusion may play an important role in the occurrence and development of VaD and AD. Big data of 1171 patients with late-onset AD in the last study showed that the early pathological changes in AD may not be an A β cascade, but a decrease in cerebral blood flow, suggesting that cerebral hypoperfusion may play an important role in cognitive decline. However, there is still a lack of systematic prospective study on the role of cerebral hypoperfusion in the early pathogenesis of VCI. Based on the establishment of a cohort of early VCI population, arterial spin labeled magnetic resonance imaging (ASL-MRI) was used to observe the changes of whole brain and regional cerebral blood flow in 300 VCIND subjects during the 3-year follow-up period. The subjects were divided into 3 groups for follow-up according to the tertile value of the relative total cerebral blood flow (rCBF) at baseline. At the same time, 100 patients with normal cognitive function matching gender, age, and education level were included as controls. The changes of cognitive function of the subjects were evaluated with a complete neuropsychological scale. The follow-up outcome indicators were as follows: VCIND progressed to VaD,VCIND progressed to AD or other types of dementia, declining VCIND, stable VCIND, and cognition remained normal. The mixed effect model was used to analyze the role of cerebral hypoperfusion in the early brain damage of VCI.
- Damage of blood-brain barrier and neural network in the early stage of VCI. The integrity of neural network is the neural basis of cognitive function, and the blood-brain barrier is an important part of neurovascular units. Previous experimental studies of investigators team have shown that chronic cerebral hypoperfusion can lead to damage of neural networks and blood-brain barrier in many brain regions, including hippocampus. The subjects were followed up longitudinally to observe the changes of blood-brain barrier and neural network. The outcome index of 3-year follow-up was as follows: VCIND progressed from VaD, to AD and other types of dementia, VCIND, stable VCIND and cognition remained normal. By comparing the multi-dimensional relationship between blood-brain barrier, neural network and cognitive outcome in time and space, the mechanism of brain function and structure damage in patients with early VCI was further revealed.
- Early VCI diagnosis prediction model based on imaging technology and its key techniques.
Previous studies have shown that the occurrence and development of VCI is not only closely related to structural MRI indexes such as cerebral infarction, cerebral atrophy and cerebral microvascular disease, but also to functional MRI indexes such as cerebral hypoperfusion and brain ultrastructural damage. However, a VCI quantitative evaluation system based on the above imaging index fusion has not been established at present. On the other hand, up to 40-80% of VCI patients have AD-like pathological changes characterized by Aβ. The impact of Aβ pathology on cognitive decline in patients with VCI and whether A β pathological indicators need to be included in the diagnosis of VCI still need to be clarified in cohort studies. This project intends to use artificial intelligence (AI) algorithm, combined with MRI vascular brain pathological damage and related factors affecting cognitive function, to build a VCI diagnosis prediction model suitable for clinical application, and verify it in the cohort study. At the same time, the Aβ molecular pathological images based on PET were integrated to establish a VCI diagnosis prediction model suitable for clinical scientific research, and further clarify the possible role of Aβ pathology in the occurrence and development of VCI.
- Establishment of VCI diagnosis and prediction model. Three hundred non-dementia subjects (including pathology of VRF and / or vascular brain damage) were enrolled. According to the clinical data, imaging data and systematic neuropsychological evaluation results, all subjects were divided into VCIND and non-VCIND (including cognitive normal or other types of cognitive impairment). The changes of cognitive function were systematically evaluated during the 3-year follow-up. Two types of outcome indicators are defined as cognitive decline and cognitive retention. The indexes of different degrees and forms of brain injury (including vascular risk factors, structural MRI, ASL-MRI and DTI) were recorded at baseline, and the corresponding quantitative analysis was carried out with the outcome index. AI algorithm was used to establish an early VCI diagnosis model suitable for clinical application. According to the cognitive outcome of the 3-year follow-up period, a model was established to predict the cognitive outcome of VCIND by imaging indicators at the baseline. In addition, 50 subjects in the VCIND group and 50 subjects in the non-VCIND group at the baseline were tested by 11C-PiB PET, and the Aβ pathological images were fused with the above-mentioned MRI images to establish a VCI diagnosis and evaluation system suitable for clinical scientific research.
- Verification of VCI diagnostic and predictive model. At the end of the 3-year follow-up, the brain damage and cognitive function of the subjects were re-evaluated. According to the newly diagnosed VCIND, the reliability and validity of the diagnostic and predictive model were verified, and the clinical application model and scientific research model were verified.The sensitivity and specificity of type A were compared and analyzed.
- A cohort study on the effect of comprehensive intervention of vascular risk factors on vascular cognitive impairment.
- Study on the effect of early comprehensive intensive intervention on vascular cognitive impairment. The purpose of this study was to establish a cohort of VCIND (n = 250) and a cohort of cognitive normal people with VRF (n=250). Each cohort was divided into two groups: comprehensive intensive intervention group and general intervention group. Comprehensive intensive intervention provides guidance on blood pressure, blood sugar, lipid regulation, exercise and other aspects according to the corresponding VRF, and formulates specific intervention programs and quality control standards. Medical staff implement tracking management and regular reminders through smart wearable devices and cloud platform data to achieve the goal of gradual intervention. General data, vascular risk factors and neuropsychological assessment were completed at baseline and 1-year, 2-year, 3-year follow-up. Mixed random effect regression model and Cox proportional hazard model were used to analyze the effects of VRF and comprehensive intervention on the outcome of end events (main outcome: dementia, secondary outcome: stroke, myocardial infarction, cognitive impairment, dementia subtype and mortality). According to the Fuminghan stroke risk subgroup, the differences of clinical effects of comprehensive intervention in different subgroups were statistically analyzed.
- Effect of comprehensive intensive intervention on early cerebral perfusion and Aβ in patients with vascular cognitive impairment.
At the end of baseline and 3-year follow-up, 50 patients in the VCIND comprehensive intensive intervention group and 50 patients in the general treatment group completed the detection of ASL cerebral blood flow and 11C-PiB PET cerebral Aβ. The effects of comprehensive intensive intervention on cerebral blood flow, Aβ and cognitive function were analyzed. To further analyze the relationship between the changes of cerebral blood flow and A β pathology, as well as its influence on cognitive function, to clarify the target and mechanism of early comprehensive intensive intervention, and to establish a perfect evaluation standard of imaging effect.
- Conditions
- Vascular Cognitive Impairment
- Being tested
- Comprehensive intensive intervention
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Comprehensive intensive interventionCombination product
- Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy
- Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake.
- Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time.
- Weight loss guidance.
| Study group | Role | What they receive |
|---|---|---|
| Comprehensive intensive intervention | Experimental | On the basis of routine management, carry out individualized cerebrovascular risk factor assessment and comprehensive intervention in a medical-nursing cooperation model, and require corresponding control indicators to be achieved. A comprehensive intervention team is established by specialized medical staff to monitor blood pressure, heart rate, exercise and other data through smart wearable devices, and automatically upload them to the cloud platform, conduct comprehensive data analysis every week, timely feedback and online reminders, establish health management files, and improve the target population The blood-brain tube risk factor control and self-management ability. Receives: Combination Product: Comprehensive intensive intervention |
| Routine management | No intervention | Only routine management was carried out for the subjects without special intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Montreal Cognitive Assessment (MoCA)
The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE.
The minimum value of Montreal Cognitive Assessment measurement is 0 and the maximum value is 30. Overall, a worse Moca score represents a worse cognitive function of the participants.
Measured: Baseline
Montreal Cognitive Assessment (MoCA)
The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE.
The minimum value of Montreal Cognitive Assessment measurement is 0 and the maximum value is 30. Overall, a worse Moca score represents a worse cognitive function of the participants.
Measured: One-year follow-up
Montreal Cognitive Assessment (MoCA)
The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE.
The minimum value of Moca measurement is 0 and the maximum value is 30. Overall, a worse Montreal Cognitive Assessment score represents a worse cognitive function of the participants.
Measured: Two-year follow-up
Montreal Cognitive Assessment (MoCA)
The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE.
The minimum value of Montreal Cognitive Assessment measurement is 0 and the maximum value is 30. Overall, a worse Moca score represents a worse cognitive function of the participants.
Measured: Three-year follow-up
Mini-Mental State Examination(MMSE)
MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function.
The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants.
Measured: Baseline
Mini-Mental State Examination(MMSE)
MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function.
The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants.
Measured: One-year follow-up
Mini-Mental State Examination(MMSE)
MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function.
The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants.
Measured: Two-year follow-up
Mini-Mental State Examination(MMSE)
MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function.
The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants.
Measured: Three-year follow-up
Secondary outcomes (16)
Auditory Verbal Learning Test(AVLT)
AVLT is used to measure participantins' instantaneous memory and delayed recall.
The minimum value of the Auditory Verbal Learning Test score is 0, and the maximum value is 12 (delayed recall) or 36 ( instantaneous memory). A higher score means better cognitive function.
Measured: Baseline
Auditory Verbal Learning Test(AVLT)
AVLT is used to measure participantins' instantaneous memory and delayed recall.
The minimum value of the Auditory Verbal Learning Test score is 0, and the maximum value is 12 (delayed recall) or 36 ( instantaneous memory). A higher score means better cognitive function.
Measured: One-year follow-up
Auditory Verbal Learning Test(AVLT)
AVLT is used to measure participantins' instantaneous memory and delayed recall.
The minimum value of the Auditory Verbal Learning Test score is 0, and the maximum value is 12 (delayed recall) or 36 ( instantaneous memory). A higher score means better cognitive function.
Measured: Two-year follow-up
Auditory Verbal Learning Test(AVLT)
AVLT is used to measure participantins' instantaneous memory and delayed recall.
The minimum value of the Auditory Verbal Learning Test score is 0, and the maximum value is 12 (delayed recall) or 36 ( instantaneous memory). A higher score means better cognitive function.
Measured: Three-year follow-up
Verbal Fluency Test (VFT)
Verbal fluency test is used to measure language ability. The minimum value of the Verbal Fluency Test score is 0. A higher score represents a better language function.
Measured: Baseline
Verbal Fluency Test (VFT)
Verbal fluency test is used to measure language ability. The minimum value of the Verbal Fluency Test score is 0. A higher score represents a better language function.
Measured: One-year follow-up
Verbal Fluency Test (VFT)
Verbal fluency test is used to measure language ability. The minimum value of the Verbal Fluency Test score is 0. A higher score represents a better language function.
Measured: Two-year follow-up
Verbal Fluency Test (VFT)
Verbal fluency test is used to measure language ability. The minimum value of the Verbal Fluency Test score is 0. A higher score represents a better language function.
Measured: Three-year follow-up
Clock Drawing Test(CDT)
CDT is used to measure visual space ability. The minimum value of the Clock Drawing Test score is 0 and the maximum value is 15. A test score lower than 12 means that the participant's visual space function is impaired.
Measured: Baseline
Clock Drawing Test(CDT)
CDT is used to measure visual space ability. The minimum value of the Clock Drawing Test score is 0 and the maximum value is 15. A test score lower than 12 means that the participant's visual space function is impaired.
Measured: One-year follow-up
Clock Drawing Test(CDT)
CDT is used to measure visual space ability. The minimum value of the Clock Drawing Test score is 0 and the maximum value is 15. A test score lower than 12 means that the participant's visual space function is impaired.
Measured: Two-year follow-up
Clock Drawing Test(CDT)
CDT is used to measure visual space ability. The minimum value of the Clock Drawing Test score is 0 and the maximum value is 15. A test score lower than 12 means that the participant's visual space function is impaired.
Measured: Three-year follow-up
Trail Making Test(TMT)
The Trail Making Test is used as an indicator of visual scanning, graphomotor speed, and executive function.
The time taken by the participants to complete the Trail Making Test and the number of errors during the test need to be recorded. The longer the participants spend, the more errors they make, and the worse their executive function is.
Measured: Baseline
Trail Making Test(TMT)
The Trail Making Test is used as an indicator of visual scanning, graphomotor speed, and executive function.
The time taken by the participants to complete the Trail Making Test and the number of errors during the test need to be recorded. The longer the participants spend, the more errors they make, and the worse their executive function is.
Measured: One-year follow-up
Trail Making Test(TMT)
The Trail Making Test is used as an indicator of visual scanning, graphomotor speed, and executive function.
The time taken by the participants to complete the Trail Making Test and the number of errors during the test need to be recorded. The longer the participants spend, the more errors they make, and the worse their executive function is.
Measured: Two-year follow-up
Trail Making Test(TMT)
The Trail Making Test is used as an indicator of visual scanning, graphomotor speed, and executive function.
The time taken by the participants to complete the Trail Making Test and the number of errors during the test need to be recorded. The longer the participants spend, the more errors they make, and the worse their executive function is.
Measured: Three-year follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2021
- Study start1 Jul 2020
- Primary completionNov 2023 (estimated)
- Study completionDec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Vascular Cognitive ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhongnan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Zhipeng Xu, Ph. D., Study director, Zhongnan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04999813
- Sponsor's protocol ID
- Junjian Zhang
- Status last verified
- Aug 2021
- First submitted
- 20 Apr 2021
- Last updated
- 11 Aug 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
He J, Song H, Zhang J. Association between neutrophil percentage-to-albumin ratio and vascular cognitive impairment in patients with cerebrovascular disease: a cross-sectional study. BMC Neurol. 2026 Apr 29;26(1):387. doi: 10.1186/s12883-026-04937-y.
PubMed 42056952
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study on Early Brain Injury Mechanism and Comprehensive Intervention of Vascular Cognitive Impairment
- ClinicalTrials.gov ID
- NCT04999813
- Acronym / sponsor ID
- Junjian Zhang
- Conditions
- Vascular Cognitive Impairment
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Zhongnan HospitalUniversity, hospital or other
- Study start
- 1 Jul 2020 (actual)
- Primary completion
- Nov 2023 (estimated)
- Study completion
- Dec 2023 (estimated)
- First posted
- 11 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Alzheimer's disease (AD) and vascular dementia (VaD) are the most common forms of senile dementia. Although the animal research of dementia has made remarkable progress, clinical trials of drugs for AD pathology have failed in recent years. The study of dementia based on cell and animal model generally aims at a single mechanism and target, and its results are quite different from the real clinical environment. More and more studies suggest that investigators should shift the focus of research to the early stage of cognitive impairment before dementia. Prevention is more important than cure, and intervention against multi-factors and multi-targets has become an important consensus. A large number of studies have shown that the mechanism of vascular brain injury plays an important role in the pathogenesis of AD and VaD, and many vascular risk factors are interventionable to some extent. Therefore, based on the clinical cohort, in-depth study of vascular cognitive impairment (Vascular cognitive impairment, VCI) has important clinical significance for the effective prevention and treatment of AD and VaD.
The leading team of the project has focused on VCI research for a long time. After nearly 20 years of experimental research and preliminary clinical observation, it is proposed that chronic cerebral ischemia can not only be a clinical disease entity, but also an important pathological basis for the early onset of VCI. This view has recently been supported by a number of authoritative international research evidence. Big data's study of 1171 patients with AD reported by Nature Commun in 2016 shows that the early pathological changes of AD may not be a cascade of amyloid protein (Aβ), but a decrease in cerebral blood flow. Therefore, this project intends to establish an early clinical research cohort of VCI to focus on three key issues in VCI research and clinical practice: (1) the theory that cerebral hypoperfusion may be an important pathological basis for the occurrence and development of VCI needs direct evidence support from clinical studies, and its mechanism needs further elucidation. (2) Based on the fusion of multimodal MRI of VCI vascular brain injury pathology and PET imaging markers of Aβ molecular pathology, a multivariate VCI cognitive evaluation model is constructed, and its sensitivity and specificity may be better than the existing VCI diagnostic standards. (3) the protective effect of early comprehensive intervention of vascular risk factors on cognitive decline in VCI may be more effective than that of single risk factor.
The first part of this project is to establish a study cohort of non-demented vascular cognitive impairment(VCIND). Neurocognitive function assessment combined with multimodal MRI including ASL, DCE, DTI and BOLD techniques were used to observe the role of cerebral hypoperfusion in the early stage and progression of VCI. At the same time, the relationship between the changes of blood-brain barrier and neural network and cognitive decline was dynamically observed to verify and explore the effect and mechanism of cognitive impairment caused by cerebral hypoperfusion. The second part studies the pathology of vascular brain injury based on MRI and the molecular pathology of A β based on PET and the relationship between Aβ molecular pathology and cognitive impairment, including the main factors affecting cognitive function, and uses artificial intelligence (AI) algorithm to develop a multiple quantitative evaluation system of VCI cognitive function, which is mainly based on the fusion of MRI and PET image markers. In the third part, a multicenter randomized controlled clinical cohort study was conducted to observe the cognitive protective effect of comprehensive intensive intervention of vascular risk factors on early VCI, so as to provide direct clinical evidence and intervention model for the prevention and treatment of VCI. The topics of the above three aspects covered by this project are closely related, which is not only a key scientific problem, but also an important clinical problem to be solved in the diagnosis and treatment of VCI.
The study of this project is expected to further clarify the role and mechanism of cerebral hypoperfusion in VCI, provide a new theoretical basis for the prevention and treatment of dementia, and develop a quantitative evaluation system of VCI cognitive function mainly based on imaging technology and AI algorithm, so as to provide a more accurate and convenient diagnostic tool for early clinical identification and scientific research of VCI. Draw up the early comprehensive intervention paradigm of VCI based on vascular risk factors and popularize it in clinic, gradually form an expert consensus, enrich and update the guidelines for diagnosis and treatment of dementia, and effectively improve the level of prevention and treatment of dementia related to VCI.
Detailed description
The main research contents of this project focus on the above three key issues: to study the role and mechanism of cerebral hypoperfusion in the early pathogenesis of VCI; to establish a predictive model for early diagnosis of MRI vascular brain damage and PET-A β pathology; to explore the clinical effect of early comprehensive intensive intervention of VRF on the prevention and treatment of VCI.
- To explore the role and mechanism of cerebral hypoperfusion in the early brain damage of VCI.
- The relationship between vascular risk factor burden and VCI Vascular risk factor (VRF) is not only an important factor in the occurrence and development of VCI, but also the main intervention target. Elucidating the relationship between VRF and VCI can provide an important theoretical basis for its early prevention and treatment. Some clinical studies have shown that long-term VRF burden is closely related to the decrease of global cerebral blood flow in young and middle-aged people without stroke, suggesting that there is a close relationship between VRF, cerebral hypoperfusion and cognitive impairment, but it needs to be further clarified in clinical cohort studies. In this project, a clinical cohort of VCIND was established, including 500 middle-aged and elderly people with VRF burden, and their complete demographic information was collected. The overall VRF burden was assessed by the Framingham Stroke risk Assessment scale, and the subjects were divided into low risk group (10-year stroke risk < 10%), medium risk group (10-year stroke risk 10%) and high-risk group (10-year stroke risk > 20%) for follow-up. The changes of cognitive function in baseline and 3-year follow-up period were measured. The relationship between VRF burden and cognitive decline in VCI was analyzed by mixed effect model, and whether decreased cerebral perfusion mediated this correlation was analyzed by mediating effect model.
- The role of cerebral hypoperfusion in the early brain damage of VCI. Many experimental studies have shown that chronic cerebral hypoperfusion may play an important role in the occurrence and development of VaD and AD. Big data of 1171 patients with late-onset AD in the last study showed that the early pathological changes in AD may not be an A β cascade, but a decrease in cerebral blood flow, suggesting that cerebral hypoperfusion may play an important role in cognitive decline. However, there is still a lack of systematic prospective study on the role of cerebral hypoperfusion in the early pathogenesis of VCI. Based on the establishment of a cohort of early VCI population, arterial spin labeled magnetic resonance imaging (ASL-MRI) was used to observe the changes of whole brain and regional cerebral blood flow in 300 VCIND subjects during the 3-year follow-up period. The subjects were divided into 3 groups for follow-up according to the tertile value of the relative total cerebral blood flow (rCBF) at baseline. At the same time, 100 patients with normal cognitive function matching gender, age, and education level were included as controls. The changes of cognitive function of the subjects were evaluated with a complete neuropsychological scale. The follow-up outcome indicators were as follows: VCIND progressed to VaD,VCIND progressed to AD or other types of dementia, declining VCIND, stable VCIND, and cognition remained normal. The mixed effect model was used to analyze the role of cerebral hypoperfusion in the early brain damage of VCI.
- Damage of blood-brain barrier and neural network in the early stage of VCI. The integrity of neural network is the neural basis of cognitive function, and the blood-brain barrier is an important part of neurovascular units. Previous experimental studies of investigators team have shown that chronic cerebral hypoperfusion can lead to damage of neural networks and blood-brain barrier in many brain regions, including hippocampus. The subjects were followed up longitudinally to observe the changes of blood-brain barrier and neural network. The outcome index of 3-year follow-up was as follows: VCIND progressed from VaD, to AD and other types of dementia, VCIND, stable VCIND and cognition remained normal. By comparing the multi-dimensional relationship between blood-brain barrier, neural network and cognitive outcome in time and space, the mechanism of brain function and structure damage in patients with early VCI was further revealed.
- Early VCI diagnosis prediction model based on imaging technology and its key techniques.
Previous studies have shown that the occurrence and development of VCI is not only closely related to structural MRI indexes such as cerebral infarction, cerebral atrophy and cerebral microvascular disease, but also to functional MRI indexes such as cerebral hypoperfusion and brain ultrastructural damage. However, a VCI quantitative evaluation system based on the above imaging index fusion has not been established at present. On the other hand, up to 40-80% of VCI patients have AD-like pathological changes characterized by Aβ. The impact of Aβ pathology on cognitive decline in patients with VCI and whether A β pathological indicators need to be included in the diagnosis of VCI still need to be clarified in cohort studies. This project intends to use artificial intelligence (AI) algorithm, combined with MRI vascular brain pathological damage and related factors affecting cognitive function, to build a VCI diagnosis prediction model suitable for clinical application, and verify it in the cohort study. At the same time, the Aβ molecular pathological images based on PET were integrated to establish a VCI diagnosis prediction model suitable for clinical scientific research, and further clarify the possible role of Aβ pathology in the occurrence and development of VCI.
- Establishment of VCI diagnosis and prediction model. Three hundred non-dementia subjects (including pathology of VRF and / or vascular brain damage) were enrolled. According to the clinical data, imaging data and systematic neuropsychological evaluation results, all subjects were divided into VCIND and non-VCIND (including cognitive normal or other types of cognitive impairment). The changes of cognitive function were systematically evaluated during the 3-year follow-up. Two types of outcome indicators are defined as cognitive decline and cognitive retention. The indexes of different degrees and forms of brain injury (including vascular risk factors, structural MRI, ASL-MRI and DTI) were recorded at baseline, and the corresponding quantitative analysis was carried out with the outcome index. AI algorithm was used to establish an early VCI diagnosis model suitable for clinical application. According to the cognitive outcome of the 3-year follow-up period, a model was established to predict the cognitive outcome of VCIND by imaging indicators at the baseline. In addition, 50 subjects in the VCIND group and 50 subjects in the non-VCIND group at the baseline were tested by 11C-PiB PET, and the Aβ pathological images were fused with the above-mentioned MRI images to establish a VCI diagnosis and evaluation system suitable for clinical scientific research.
- Verification of VCI diagnostic and predictive model. At the end of the 3-year follow-up, the brain damage and cognitive function of the subjects were re-evaluated. According to the newly diagnosed VCIND, the reliability and validity of the diagnostic and predictive model were verified, and the clinical application model and scientific research model were verified.The sensitivity and specificity of type A were compared and analyzed.
- A cohort study on the effect of comprehensive intervention of vascular risk factors on vascular cognitive impairment.
- Study on the effect of early comprehensive intensive intervention on vascular cognitive impairment. The purpose of this study was to establish a cohort of VCIND (n = 250) and a cohort of cognitive normal people with VRF (n=250). Each cohort was divided into two groups: comprehensive intensive intervention group and general intervention group. Comprehensive intensive intervention provides guidance on blood pressure, blood sugar, lipid regulation, exercise and other aspects according to the corresponding VRF, and formulates specific intervention programs and quality control standards. Medical staff implement tracking management and regular reminders through smart wearable devices and cloud platform data to achieve the goal of gradual intervention. General data, vascular risk factors and neuropsychological assessment were completed at baseline and 1-year, 2-year, 3-year follow-up. Mixed random effect regression model and Cox proportional hazard model were used to analyze the effects of VRF and comprehensive intervention on the outcome of end events (main outcome: dementia, secondary outcome: stroke, myocardial infarction, cognitive impairment, dementia subtype and mortality). According to the Fuminghan stroke risk subgroup, the differences of clinical effects of comprehensive intervention in different subgroups were statistically analyzed.
- Effect of comprehensive intensive intervention on early cerebral perfusion and Aβ in patients with vascular cognitive impairment.
At the end of baseline and 3-year follow-up, 50 patients in the VCIND comprehensive intensive intervention group and 50 patients in the general treatment group completed the detection of ASL cerebral blood flow and 11C-PiB PET cerebral Aβ. The effects of comprehensive intensive intervention on cerebral blood flow, Aβ and cognitive function were analyzed. To further analyze the relationship between the changes of cerebral blood flow and A β pathology, as well as its influence on cognitive function, to clarify the target and mechanism of early comprehensive intensive intervention, and to establish a perfect evaluation standard of imaging effect.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Comprehensive intensive intervention | Experimental | Combination Product: Comprehensive intensive interventionOn the basis of routine management, carry out individualized cerebrovascular risk factor assessment and comprehensive intervention in a medical-nursing cooperation model, and require corresponding control indicators to be achieved. A comprehensive intervention team is established by specialized medical staff to monitor blood pressure, heart rate, exercise and other data through smart wearable devices, and automatically upload them to the cloud platform, conduct comprehensive data analysis every week, timely feedback and online reminders, establish health management files, and improve the target population The blood-brain tube risk factor control and self-management ability. |
| Routine management | No intervention | –Only routine management was carried out for the subjects without special intervention. |
Who may qualify
- Ages
- 50 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- ①Healthy volunteers or VCIND patients(Diagnostic criteria comply with the "Guidelines for the Diagnosis and Treatment of Vascular Cognitive Impairment" formulated by the Dementia and Cognitive Impairment Group of the Neurology Branch of the Chinese Medical Association);
- ②Age between 50-70 years old;
- ③Able to accept and cooperate in completing various instrumental examinations and neuropsychological examinations Scale testing;
- ④Agree to sign an informed consent form.
Key exclusion criteria (7 listed)
- ①Combined with other serious diseases, life expectancy is less than 3 years;
- ②Patients with vision and hearing impairment that significantly affect cognitive testing;
- ③Severe heart, brain, lung, kidney and other diseases;
- ④Have a history of psychoactive substance abuse;
- ⑤Have other serious physical diseases that affect cognitive testing, such as coma, epilepsy, hypothyroidism , Hypoxemia, etc.;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Comprehensive intensive intervention* Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy * Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake. * Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time. * Weight loss guidance. | Combination product | Comprehensive intensive intervention |
Primary outcome
Montreal Cognitive Assessment (MoCA)
Time frame: Baseline
The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE. The minimum value of Montreal Cognitive Assessment measurement is 0 and the maximum value is 30. Overall, a worse Moca score represents a worse cognitive function of the participants.
Montreal Cognitive Assessment (MoCA)
Time frame: One-year follow-up
The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE. The minimum value of Montreal Cognitive Assessment measurement is 0 and the maximum value is 30. Overall, a worse Moca score represents a worse cognitive function of the participants.
Montreal Cognitive Assessment (MoCA)
Time frame: Two-year follow-up
The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE. The minimum value of Moca measurement is 0 and the maximum value is 30. Overall, a worse Montreal Cognitive Assessment score represents a worse cognitive function of the participants.
Montreal Cognitive Assessment (MoCA)
Time frame: Three-year follow-up
The scores of the MoCA tests are used to evaluate the cognitive function of the subjects. MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for measuring multiple cognitive domains which are important components not measured by the MMSE. The minimum value of Montreal Cognitive Assessment measurement is 0 and the maximum value is 30. Overall, a worse Moca score represents a worse cognitive function of the participants.
Mini-Mental State Examination(MMSE)
Time frame: Baseline
MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function. The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants.
Mini-Mental State Examination(MMSE)
Time frame: One-year follow-up
MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function. The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants.
Mini-Mental State Examination(MMSE)
Time frame: Two-year follow-up
MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function. The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants.
Mini-Mental State Examination(MMSE)
Time frame: Three-year follow-up
MMSE is used as a screening scale for cognitive impairment, can measure the participants' global cognitive function. The minimum value of the Mini-Mental State Examination measurement value is 0 and the maximum value is 30. A worse MMSE score represents a worse cognitive function of the participants.
16 secondary outcomes
Auditory Verbal Learning Test(AVLT)
Time frame: Baseline
Auditory Verbal Learning Test(AVLT)
Time frame: One-year follow-up
Auditory Verbal Learning Test(AVLT)
Time frame: Two-year follow-up
Auditory Verbal Learning Test(AVLT)
Time frame: Three-year follow-up
Verbal Fluency Test (VFT)
Time frame: Baseline
Verbal Fluency Test (VFT)
Time frame: One-year follow-up
Verbal Fluency Test (VFT)
Time frame: Two-year follow-up
Verbal Fluency Test (VFT)
Time frame: Three-year follow-up
Clock Drawing Test(CDT)
Time frame: Baseline
Clock Drawing Test(CDT)
Time frame: One-year follow-up
Clock Drawing Test(CDT)
Time frame: Two-year follow-up
Clock Drawing Test(CDT)
Time frame: Three-year follow-up
Trail Making Test(TMT)
Time frame: Baseline
Trail Making Test(TMT)
Time frame: One-year follow-up
Trail Making Test(TMT)
Time frame: Two-year follow-up
Trail Making Test(TMT)
Time frame: Three-year follow-up
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2021.
- Derived from this study: PubMed 42056952He J, Song H, Zhang J. Association between neutrophil percentage-to-albumin ratio and vascular cognitive impairment in patients with cerebrovascular disease: a cross-sectional study. BMC Neurol. 2026 Apr 29;26(1):387. doi: 10.1186/s12883-026-04937-y.
- Individual participant dataSharing planned: Undecided
Related trials for Vascular Cognitive Impairment
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Not yet recruitingObservational study
Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Not yet recruiting
COG+OT Telerehabilitation for Adults With Subjective Cognitive Complaints
Subjective Cognitive Complaints, Ehlers-Danlos Syndrome
RecruitingObservational study
China HEalthy Aging and Dementia Study (HEAD)
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zhipeng Xu, Ph. D. study director
Zhongnan Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Comprehensive intensive intervention in people with Vascular Cognitive Impairment, run by Zhongnan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 11 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Junjian Zhang, Ph. D. (13986225751, xsssm@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Montreal Cognitive Assessment (MoCA) (time frame: Baseline). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04999813, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2021.